About New England Biolabs
New England Biolabs is a company based in Ipswich (United Kingdom) founded in 1970 by Donald Comb. The company has 50 employees as of December 31, 2022. New England Biolabs has completed 1 acquisition, including Fluorogenics. New England Biolabs operates in a competitive market with competitors including Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.
- Headquarter Ipswich, United Kingdom
- Employees 50 as on 31 Dec, 2022
- Founders Donald Comb
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name N.E.B. Ltd
- Date of Incorporation 31 Jan, 2023
- Jurisdiction WEDNESBURY, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$10.75 K (USD), Grant
Jun 01, 2018
-
Investors
HHS
& 3 more
-
Employee Count
50
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of New England Biolabs
Unlock access to complete
Unlock access to complete
Funding Insights of New England Biolabs
Investors in New England Biolabs
New England Biolabs has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Massachusetts Life Sciences Center and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences innovation is supported through funding and programs.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for New England Biolabs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by New England Biolabs
New England Biolabs has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fluorogenics.
Investment portfolio details for New England Biolabs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Lyophilized reagents for stable nucleic acid amplification are supplied.
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for New England Biolabs
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - New England Biolabs
Detailed financials for New England Biolabs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
New England Biolabs Comparisons
Peer comparison for New England Biolabs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of New England Biolabs
New England Biolabs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neogen, Parse Biosciences, Qiagen, Biofidelity and Fluent BioSciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Proprietary reagents for single-cell genetic analysis are developed.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
Detailed competitors of New England Biolabs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on New England Biolabs
Complete news archive for New England Biolabs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about New England Biolabs
New England Biolabs was founded in 1970 and raised its 1st funding round 24 years after it was founded.
New England Biolabs is headquartered in Ipswich, United Kingdom.
James Ellard is the current CEO of New England Biolabs.
As of Dec 31, 2022, the latest employee count at New England Biolabs is 50.
Founded in 1970, New England Biolabs operates in the molecular biology sector from Ipswich, United Kingdom. Discovery, development, and commercialization of reagents and kits are focused on genetic engineering, synthetic biology, and genomics. Over 200 recombinant and 30 native restriction enzymes, along with nicking enzymes and DNA methylases, form the core portfolio. Research and development in these areas are supported globally.
New England Biolabs's top competitors include Neogen, Qiagen and Parse Biosciences.
New England Biolabs has made 1 acquisition, including Fluorogenics.
New England Biolabs has 4 investors. Key investors include HHS, Massachusetts Life Sciences Center, NIH SBIR/STTR, and National Science Foundation.